-
1
-
-
0031720795
-
Is type II diabetes mellitus a disease of the innate immune system?
-
Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
-
(1998)
Diabetologia
, vol.41
, pp. 1241-1248
-
-
Pickup, J.C.1
Crook, M.A.2
-
2
-
-
40749148910
-
Innate immunity, insulin resistance and type 2 diabetes
-
Fernandez-Real J.M., Pickup J.C. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2008, 19:10-16.
-
(2008)
Trends Endocrinol Metab
, vol.19
, pp. 10-16
-
-
Fernandez-Real, J.M.1
Pickup, J.C.2
-
3
-
-
33644757817
-
Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein
-
Gubern C., Lopez-Bermejo A., Biarnes J., Vendrell J., Ricart W., Fernandez-Real J.M. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 2006, 55:216-224.
-
(2006)
Diabetes
, vol.55
, pp. 216-224
-
-
Gubern, C.1
Lopez-Bermejo, A.2
Biarnes, J.3
Vendrell, J.4
Ricart, W.5
Fernandez-Real, J.M.6
-
4
-
-
34247379008
-
Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans
-
Lopez-Bermejo A., Chico-Julia B., Castro A., et al. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2007, 27:1166-1171.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 1166-1171
-
-
Lopez-Bermejo, A.1
Chico-Julia, B.2
Castro, A.3
-
5
-
-
70349923422
-
Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes
-
Moreno-Navarrete J.M., Ortega F.J., Bassols J., Ricart W., Fernandez-Real J.M. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab 2009, 94:4036-4044.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 4036-4044
-
-
Moreno-Navarrete, J.M.1
Ortega, F.J.2
Bassols, J.3
Ricart, W.4
Fernandez-Real, J.M.5
-
6
-
-
70349656625
-
Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002
-
Herder C., Zierer A., Koenig W., Roden M., Meisinger C., Thorand B. Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diab Care 2009, 32:1921-1923.
-
(2009)
Diab Care
, vol.32
, pp. 1921-1923
-
-
Herder, C.1
Zierer, A.2
Koenig, W.3
Roden, M.4
Meisinger, C.5
Thorand, B.6
-
7
-
-
77951655973
-
Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study
-
Carstensen M., Herder C., Brunner E.J., et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 2010, 162:913-917.
-
(2010)
Eur J Endocrinol
, vol.162
, pp. 913-917
-
-
Carstensen, M.1
Herder, C.2
Brunner, E.J.3
-
8
-
-
77951831569
-
Accelerated increase in serum interleukin-1 receptor antagonist starts 6years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study
-
Carstensen M., Herder C., Kivimaki M., et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010, 59:1222-1227.
-
(2010)
Diabetes
, vol.59
, pp. 1222-1227
-
-
Carstensen, M.1
Herder, C.2
Kivimaki, M.3
-
9
-
-
0022978893
-
Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus
-
Heinzel R., Appelhans H., Gassen G., et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur J Biochem 1986, 160:61-67.
-
(1986)
Eur J Biochem
, vol.160
, pp. 61-67
-
-
Heinzel, R.1
Appelhans, H.2
Gassen, G.3
-
10
-
-
0012030796
-
Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase
-
Thompson R.C., Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986, 83:6692-6696.
-
(1986)
Proc Natl Acad Sci USA
, vol.83
, pp. 6692-6696
-
-
Thompson, R.C.1
Ohlsson, K.2
-
11
-
-
0027133240
-
In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2
-
Mulligan M.S., Desrochers P.E., Chinnaiyan A.M., et al. In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci USA 1993, 90:11523-11527.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 11523-11527
-
-
Mulligan, M.S.1
Desrochers, P.E.2
Chinnaiyan, A.M.3
-
12
-
-
0030941175
-
Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide
-
Jin F.Y., Nathan C., Radzioch D., Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997, 88:417-426.
-
(1997)
Cell
, vol.88
, pp. 417-426
-
-
Jin, F.Y.1
Nathan, C.2
Radzioch, D.3
Ding, A.4
-
13
-
-
0032590012
-
Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation
-
Lentsch A.B., Jordan J.A., Czermak B.J., et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999, 154:239-247.
-
(1999)
Am J Pathol
, vol.154
, pp. 239-247
-
-
Lentsch, A.B.1
Jordan, J.A.2
Czermak, B.J.3
-
14
-
-
30344465763
-
SLPI and elafin: one glove, many fingers
-
Williams S.E., Brown T.I., Roghanian A., Sallenave J.M. SLPI and elafin: one glove, many fingers. Clin Sci Lond 2006, 110:21-35.
-
(2006)
Clin Sci Lond
, vol.110
, pp. 21-35
-
-
Williams, S.E.1
Brown, T.I.2
Roghanian, A.3
Sallenave, J.M.4
-
15
-
-
0033575758
-
Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis
-
Song X., Zeng L., Jin W., et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999, 190:535-542.
-
(1999)
J Exp Med
, vol.190
, pp. 535-542
-
-
Song, X.1
Zeng, L.2
Jin, W.3
-
16
-
-
0141569328
-
Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury
-
Wang X., Li X., Xu L., et al. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol Pharmacol 2003, 64:833-840.
-
(2003)
Mol Pharmacol
, vol.64
, pp. 833-840
-
-
Wang, X.1
Li, X.2
Xu, L.3
-
17
-
-
0035897696
-
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
18
-
-
0031671469
-
Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance
-
Fernandez-Real J.M., Broch M., Ricart W., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998, 47:1757-1762.
-
(1998)
Diabetes
, vol.47
, pp. 1757-1762
-
-
Fernandez-Real, J.M.1
Broch, M.2
Ricart, W.3
-
19
-
-
0022797049
-
MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test
-
Pacini G., Bergman R.N. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986, 23:113-122.
-
(1986)
Comput Methods Programs Biomed
, vol.23
, pp. 113-122
-
-
Pacini, G.1
Bergman, R.N.2
-
20
-
-
0024834748
-
Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach
-
Bergman R.N. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989, 38:1512-1527.
-
(1989)
Diabetes
, vol.38
, pp. 1512-1527
-
-
Bergman, R.N.1
-
21
-
-
39749199066
-
Association of Circulating Lactoferrin Concentration and 2 Nonsynonymous LTF Gene Polymorphisms with Dyslipidemia in Men Depends on Glucose-Tolerance Status
-
Moreno J.M., Ortega F.J., Bassols J., Castro A., Ricart W., Fernandez-Real J.M. Association of Circulating Lactoferrin Concentration and 2 Nonsynonymous LTF Gene Polymorphisms with Dyslipidemia in Men Depends on Glucose-Tolerance Status. Clin Chem 2008, 54:301-309.
-
(2008)
Clin Chem
, vol.54
, pp. 301-309
-
-
Moreno, J.M.1
Ortega, F.J.2
Bassols, J.3
Castro, A.4
Ricart, W.5
Fernandez-Real, J.M.6
-
22
-
-
0034075048
-
Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia
-
Grobmyer S.R., Barie P.S., Nathan C.F., et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000, 28:1276-1282.
-
(2000)
Crit Care Med
, vol.28
, pp. 1276-1282
-
-
Grobmyer, S.R.1
Barie, P.S.2
Nathan, C.F.3
-
23
-
-
0028675419
-
Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes
-
Sallenave J.M., Shulmann J., Crossley J., Jordana M., Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994, 11:733-741.
-
(1994)
Am J Respir Cell Mol Biol
, vol.11
, pp. 733-741
-
-
Sallenave, J.M.1
Shulmann, J.2
Crossley, J.3
Jordana, M.4
Gauldie, J.5
-
24
-
-
0034581627
-
The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease
-
Sallenave J.M. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 2000, 1:87-92.
-
(2000)
Respir Res
, vol.1
, pp. 87-92
-
-
Sallenave, J.M.1
-
25
-
-
0034888485
-
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers
-
Waring W.S., Webb D.J., Maxwell S.R. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001, 38:365-371.
-
(2001)
J Cardiovasc Pharmacol
, vol.38
, pp. 365-371
-
-
Waring, W.S.1
Webb, D.J.2
Maxwell, S.R.3
-
26
-
-
10744227545
-
Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress
-
Wagenaar G.T., ter Horst S.A., van Gastelen M.A., et al. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 2004, 36:782-801.
-
(2004)
Free Radic Biol Med
, vol.36
, pp. 782-801
-
-
Wagenaar, G.T.1
ter Horst, S.A.2
van Gastelen, M.A.3
-
27
-
-
0037416147
-
Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice
-
Nakamura A., Mori Y., Hagiwara K., et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003, 197:669-674.
-
(2003)
J Exp Med
, vol.197
, pp. 669-674
-
-
Nakamura, A.1
Mori, Y.2
Hagiwara, K.3
-
28
-
-
0027136230
-
In vivo protection against endotoxin by plasma high density lipoprotein
-
Levine D.M., Parker T.S., Donnelly T.M., Walsh A., Rubin A.L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993, 90:12040-12044.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 12040-12044
-
-
Levine, D.M.1
Parker, T.S.2
Donnelly, T.M.3
Walsh, A.4
Rubin, A.L.5
-
29
-
-
0032773727
-
Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages
-
Ding A., Thieblemont N., Zhu J., Jin F., Zhang J., Wright S. Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect Immun 1999, 67:4485-4489.
-
(1999)
Infect Immun
, vol.67
, pp. 4485-4489
-
-
Ding, A.1
Thieblemont, N.2
Zhu, J.3
Jin, F.4
Zhang, J.5
Wright, S.6
-
30
-
-
0030802997
-
Potency of truncated secretory leukoprotease inhibitor assessed in acute lung injury models in hamsters
-
Mitsuhashi H., Asano S., Nonaka T., Masuda K., Kiyoki M. Potency of truncated secretory leukoprotease inhibitor assessed in acute lung injury models in hamsters. J Pharmacol Exp Ther 1997, 282:1005-1010.
-
(1997)
J Pharmacol Exp Ther
, vol.282
, pp. 1005-1010
-
-
Mitsuhashi, H.1
Asano, S.2
Nonaka, T.3
Masuda, K.4
Kiyoki, M.5
-
31
-
-
0037047070
-
Allopurinol improves endothelial dysfunction in chronic heart failure
-
Farquharson C., Butler R., Hill A., Belch J., Struthers A. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
-
(2002)
Circulation
, vol.106
, pp. 221-226
-
-
Farquharson, C.1
Butler, R.2
Hill, A.3
Belch, J.4
Struthers, A.5
-
32
-
-
34447341178
-
The paradox of dysfunctional high-density lipoprotein
-
Ansell B., Fonarow G., Fogelman A. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007, 18:427-434.
-
(2007)
Curr Opin Lipidol
, vol.18
, pp. 427-434
-
-
Ansell, B.1
Fonarow, G.2
Fogelman, A.3
|